- 1、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
胃癌治疗现状及2008ASCO进展课件
胃癌治疗现状及2008ASCO进展 Rui-hua Xu (徐瑞华) Sun Yat-sen University Cancer Center xurh@ Tel: 020-8734 3468 胃癌治疗有效的化疗药物 Old Drugs Fluoropyrimidines 5-FU Platinum Cisplatin Anthracyclines Doxorubicin Epirubicin Etoposide Methotrexate New Drugs Fluoropyrimidines Capecitabine S-1 Platinum Oxaliplatin Taxanes Paclitaxel Docetaxel Irinotecan FP vs FAM vs UFTM: JCOG 9912 trial ECF vs FAMTX: UK Trial Chemotherapy for gastric cancer in the past Where we have been in AGC我们所知道的胃癌化疗 Eloxatin: REAL-2, phase III Xeloda: ML17032, phase III Taxotere: TAX 325, phase III CPT-11 V306, phase III Eloxatin: FLO vs FLP, phase III S1: JCOG 9912, phase III S1: SPIRITS, phase III 2008 ASCO DC vs FLP phase III Phase II clinical trials REAL-2: 研究设计 REAL-2: overall survival for fluoropyrimidine comparison (per protocol) REAL-2: overall survival for platinum comparison (per protocol) REAL-2: overall survival for ECFand EOX (ITT) REAL-2: grade 3–4 血液学毒性 Best Overall Response (ITT) Time to Treatment Failure (ITT) FLO vs FLP: subgroup of patients over 65 years Grade ? Hematological and Neurosensory toxicities ML17032 : Phase III study: XP vs FPXeloda + cisplatin vs 5-FU + cisplatin XP vs FP: non-inferior PFS XP vs FP: trend to superior PFS Superior response rate with XP vs FP Docetaxel-based chemotherapy in advanced gastric cancer: Phase III trial (TAX 325) TAX 325: time to progression(primary endpoint) TAX 325: overall survival TAX 325: best overall response TAX 325 Clinical Benefit: time to definitive worsening of KPSa TAX 325: main grade 3–4 non-hematologic adverse events TAX 325: grade 3–4 hematologic adverse events TAX325: Conclusions andinterpretations T + CF CF The TCF regimen is the proof of the concept that docetaxel provides the benefit our patients need Docetaxel should be incorporated in safer regimen using oxaliplatin, S-1 or capecitabine Develop a re
有哪些信誉好的足球投注网站
文档评论(0)